Causal Relationship Between Plasma VEGF Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study

Causal Association Between Plasma Vascular Endothelial Growth Factor Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06620068

Acronym

VEGF PP

Enrollment

207473

Registered

2024-10-01

Start date

2024-09-25

Completion date

2024-12-01

Last updated

2024-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Placenta Previa

Keywords

Vascular Endothelial Growth Factor (VEGF), Mendelian Randomization, Angiogenesis, Pregnancy Complications, Placental Development

Brief summary

This study aims to investigate the causal relationship between plasma vascular endothelial growth factor (VEGF) family proteins and placenta previa using a two-sample Mendelian randomization (MR) approach. Genome-wide association study (GWAS) data will be analyzed to assess the correlation and potential causality between VEGF protein levels and the occurrence of placenta previa.

Detailed description

Placenta previa is a serious complication during pregnancy, leading to significant risks for both the mother and the fetus. This study utilizes Mendelian randomization (MR) to explore the potential causal link between plasma levels of VEGF family proteins (including VEGFA, VEGFB, VEGFC, VEGFD, and PLGF) and the risk of placenta previa. By using genome-wide association study (GWAS) data from the UK Biobank and FinnGen datasets, the study aims to provide insights into the role of angiogenesis and abnormal placental development. The MR analysis will help minimize confounding factors and provide robust evidence regarding the causal relationship between VEGF proteins and placenta previa.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Participants included in genome-wide association studies (GWAS) with available data on plasma VEGF family proteins and placenta previa.

Exclusion criteria

* Participants with incomplete or missing data on plasma VEGF levels or placenta previa.

Design outcomes

Primary

Measure	Time frame	Description
Causal relationship between plasma VEGFA levels and the risk of placenta previa	Data analysis and outcome assessment will be completed by December 2024	This outcome measures the association between plasma VEGFA levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.

Secondary

Measure	Time frame	Description
Causal relationship between plasma VEGFB levels and the risk of placenta previa	Data analysis and outcome assessment will be completed by December 2024	This outcome measures the association between plasma VEGFB levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.
Causal relationship between plasma VEGFC levels and the risk of placenta previa	Data analysis and outcome assessment will be completed by December 2024	This outcome measures the association between plasma VEGFC levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.
Causal relationship between plasma PLGF levels and the risk of placenta previa	Data analysis and outcome assessment will be completed by December 2024	This outcome measures the association between plasma PLGF levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.

Contacts

Primary ContactZhibin Xu

unignorable_xuzhibin@outlook.com+8615816832640

Outcome results